Noninvasive Cardiac Imaging in Patients With Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology

Volumn 48, Issue 12, 2006, Pages 2410-2422

  Nagueh, Sherif F ^a   Mahmarian, John J ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DILTIAZEM; DISOPYRAMIDE; HEART RECEPTOR; VERAPAMIL;

ARTIFICIAL HEART PACEMAKER; ATHLETE; BLOOD FLOW; DIASTOLIC BLOOD PRESSURE; DIFFERENTIAL DIAGNOSIS; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; HEART DEATH; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART LEFT VENTRICLE PERFORMANCE; HEART MUSCLE METABOLISM; HEART MUSCLE PERFUSION; HEMODYNAMICS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; METHODOLOGY; MITRAL VALVE REGURGITATION; MONITORING; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROVOCATION; REVIEW; SCREENING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTOLIC BLOOD PRESSURE; TISSUE CHARACTERIZATION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

CARDIOMYOPATHY, HYPERTROPHIC; ECHOCARDIOGRAPHY; HUMANS; MAGNETIC RESONANCE IMAGING; SPORTS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33845340783     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.07.065     Document Type: Review

References (78)

1. Maron B.J., McKenna W.J., Danielson G.K., et al., Task Force on Clinical Expert Consensus Documents, American College of Cardiology, Committee for Practice Guidelines, European Society of Cardiology American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice GuidelinesJ Am Coll Cardiol 42 (2003) 1687-1713
2. Marian A.J., and Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 33 (2001) 655-670
3. Wigle E.D., Sasson Z., Henderson M.A., et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 28 (1985) 1-83
4. Spirito P., and Maron B.J. Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. J Am Coll Cardiol 15 (1990) 1521-1526
5. Spirito P., Bellone P., Harris K.M., Bernabo P., Bruzzi P., and Maron B.J. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342 (2000) 1778-1785
6. Kato T.S., Noda A., Izawa H., et al. Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. Circulation 110 (2004) 3808-3814
7. Topol E.J., Traill T.A., and Fortuin N.J. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 312 (1985) 277-283
8. Maslow A.D., Regan M.M., Haering J.M., Johnson R.G., and Levine R.A. Echocardiographic predictors of left ventricular outflow tract obstruction and systolic anterior motion of the mitral valve after mitral valve reconstruction for myxomatous valve disease. J Am Coll Cardiol 34 (1999) 2096-2104
9. Pieroni M., Chimenti C., De Cobelli F., et al. Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol 47 (2006) 1663-1671
10. Sharma S., Maron B.J., Whyte G., Firoozi S., Elliott P.M., and McKenna W.J. Physiologic limits of left ventricular hypertrophy in elite junior athletes: relevance to differential diagnosis of athlete's heart and hypertrophic cardiomyopathy. J Am Coll Cardiol 40 (2002) 1431-1436
11. Rajiv C., Vinereanu D., and Fraser A.G. Tissue Doppler imaging for the evaluation of patients with hypertrophic cardiomyopathy. Curr Opin Cardiol 19 (2004) 430-436
12. Nishimura R.A., Appleton C.P., Redfield M.M., Ilstrup D.M., Holmes Jr. D.R., and Tajik A.J. Noninvasive Doppler echocardiographic evaluation of left ventricular filling pressures in patients with cardiomyopathies: a simultaneous Doppler echocardiographic and cardiac catheterization study. J Am Coll Cardiol 28 (1996) 1226-1233
13. Nagueh S.F., Lakkis N.M., Middleton K.J., Spencer III W.H., Zoghbi W.A., and Quinones M.A. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 99 (1999) 254-261
14. Nagueh S.F., Lakkis N.M., Middleton K.J., et al. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 99 (1999) 344-347
15. Sitges M., Shiota T., Lever H.M., et al. Comparison of left ventricular diastolic function in obstructive hypertrophic cardiomyopathy in patients undergoing percutaneous septal alcohol ablation versus surgical myotomy/myectomy. Am J Cardiol 91 (2003) 817-821
16. Matsumura Y., Elliott P.M., Virdee M.S., Sorajja P., Doi Y., and McKenna W.J. Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: relation to symptoms and exercise capacity. Heart 87 (2002) 247-251
17. McMahon C.J., Nagueh S.F., Pignatelli R.H., et al. Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation 109 (2004) 1756-1762
18. Woo A., Williams W.G., Choi R., et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 111 (2005) 2033-2041
19. Sherrid M.V., Chu C.K., Delia E., Mogtader A., and Dwyer Jr. E.M. An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy. J Am Coll Cardiol 22 (1993) 816-825
20. Sherrid M.V., Gunsburg D.Z., Moldenhauer S., and Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 36 (2000) 1344-1354
21. Maron M.S., Olivotto I., Betocchi S., et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348 (2003) 295-303
22. Lakkis N., Plana J.C., Nagueh S., Killip D., Roberts R., and Spencer III W.H. Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients. Am J Cardiol 88 (2001) 583-586
23. Yu E.H., Omran A.S., Wigle E.D., Williams W.G., Siu S.C., and Rakowski H. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol 36 (2000) 2219-2225
24. Schwammenthal E., Nakatani S., He S., et al. Mechanism of mitral regurgitation in hypertrophic cardiomyopathy: mismatch of posterior to anterior leaflet length and mobility. Circulation 98 (1998) 856-865
25. Flores-Ramirez R., Lakkis N.M., Middleton K.J., Killip D., Spencer III W.H., and Nagueh S.F. Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 37 (2001) 208-214
26. Nakatani S., Schwammenthal E., Lever H.M., Levine R.A., Lytle B.W., and Thomas J.D. New insights into the reduction of mitral valve systolic anterior motion after ventricular septal myectomy in hypertrophic obstructive cardiomyopathy. Am Heart J 131 (1996) 294-300
27. Sherrid M.V., Pearle G., and Gunsburg D.Z. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation 97 (1998) 41-47
28. Ito T., Suwa M., Sakai Y., Hozumi T., and Kitaura Y. Usefulness of tissue Doppler imaging for demonstrating altered septal contraction sequence during dual-chamber pacing in obstructive hypertrophic cardiomyopathy. Am J Cardiol 96 (2005) 1558-1562
29. Nagueh S.F., Lakkis N.M., He Z.X., et al. Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 32 (1998) 225-229
30. Faber L., Seggewiss H., and Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 98 (1998) 2415-2421
31. Monakier D., Woo A., Puri T., et al. Usefulness of myocardial contrast echocardiographic quantification of risk area for predicting postprocedural complications in patients undergoing septal ethanol ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 94 (2004) 1515-1522
32. Mazur W., Nagueh S.F., Lakkis N.M., et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 103 (2001) 1492-1496
33. Park T.H., Lakkis N.M., Middleton K.J., et al. Acute effect of nonsurgical septal reduction therapy on regional left ventricular asynchrony in patients with hypertrophic obstructive cardiomyopathy. Circulation 106 (2002) 412-415
34. Nagueh S.F., Stetson S.J., Lakkis N.M., et al. Decreased expression of tumor necrosis factor-alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy. Circulation 103 (2001) 1844-1850
35. Nagueh S.F., Lakkis N.M., Middleton K.J., et al. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 34 (1999) 1123-1128
36. Ommen S.R., Park S.H., Click R.L., Freeman W.K., Schaff H.V., and Tajik A.J. Impact of intraoperative transesophageal echocardiography in the surgical management of hypertrophic cardiomyopathy. Am J Cardiol 90 (2002) 1022-1024
37. Minakata K., Dearani J.A., Schaff H.V., O'Leary P.W., Ommen S.R., and Danielson G.K. Mechanisms for recurrent left ventricular outflow tract obstruction after septal myectomy for obstructive hypertrophic cardiomyopathy. Ann Thorac Surg 80 (2005) 851-856
38. Maron B.J., Seidman J.G., and Seidman C.E. Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. J Am Coll Cardiol 44 (2004) 2125-2132
39. Nagueh S.F., McFalls J., Meyer D., et al. Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation 108 (2003) 395-398
40. Forissier J.F., Charron P., Tezenas du Montcel S., et al. Diagnostic accuracy of a 2D left ventricle hypertrophy score for familial hypertrophic cardiomyopathy. Eur Heart J 26 (2005) 1882-1886
41. Nagueh S.F., Kopelen H.A., Lim D.S., et al. Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 102 (2000) 1346-1350
42. Nagueh S.F., Bachinski L.L., Meyer D., et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 104 (2001) 128-130
43. Ho C.Y., Sweitzer N.K., McDonough B., et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 105 (2002) 2992-2997
44. Cardim N., Perrot A., Ferreira T., et al. Usefulness of Doppler myocardial imaging for identification of mutation carriers of familial hypertrophic cardiomyopathy. Am J Cardiol 90 (2002) 128-132
45. McTaggart D.R. Diltiazem reverses tissue Doppler velocity abnormalities in pre-clinical hypertrophic cardiomyopathy. Heart Lung Circ 13 (2004) 39-40
46. Pieroni M., Chimenti C., Ricci R., Sale P., Russo M.A., and Frustaci A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 107 (2003) 1978-1984
47. Bonow R.O., Dilsizian V., Rosing D.R., Maron B.J., Bacharach S.L., and Green M.V. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation 72 (1985) 853-864
48. Keng F.Y., Chang S.M., Cwajg E., et al. Gated SPECT in patients with hypertrophic obstructive cardiomyopathy undergoing transcoronary ethanol septal ablation. J Nucl Cardiol 9 (2002) 594-600
49. Dilsizian V., Bonow R.O., Epstein S.E., and Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 22 (1993) 796-804
50. Cecchi F., Olivotto I., Gistri R., Lorenzoni R., Chiriatti G., and Camici P.G. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349 (2003) 1027-1035
51. Buyukdereli G., Kanadasi M., and Kibar M. Washout rates of Tc-99m tetrofosmin in asymmetric septal hypertrophy. Ann Nucl Med 19 (2005) 29-33
52. Cannon III R.O., Dilsizian V., O'Gara P.T., et al. Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy. Circulation 85 (1992) 1039-1045
53. Zhao C., Shuke N., Okizaki A., et al. Comparison of myocardial fatty acid metabolism with left ventricular function and perfusion in cardiomyopathies: by 123I-BMIPP SPECT and 99mTc-tetrofosmin electrocardiographically gated SPECT. Ann Nucl Med 17 (2003) 541-548
54. Terai H., Shimizu M., Ino H., et al. Cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy with malignant ventricular tachyarrhythmias. J Nucl Cardiol 10 (2003) 304-310
55. Terai H., Shimizu M., Ino H., et al. Changes in cardiac sympathetic nerve innervation and activity in pathophysiologic transition from typical to end-stage hypertrophic cardiomyopathy. J Nucl Med 44 (2003) 1612-1617
56. Lefroy D.C., de Silva R., Choudhury L., et al. Diffuse reduction of myocardial beta adrenoceptors in hypertrophic cardiomyopathy: a study with positron emission tomography. J Am Coll Cardiol 22 (1993) 1653-1660
57. Schafers M., Dutka D., Rhodes C.G., et al. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy. Circ Res 82 (1998) 57-62
58. Choudhury L., Guzzetti S., Lefroy D.C., et al. Myocardial beta adrenoceptors and left ventricular function in hypertrophic cardiomyopathy. Heart 75 (1996) 50-54
59. Pennell D.J., Sechtem U.P., Higgins C.B., et al., Society for Cardiovascular Magnetic Resonance, Working Group on Cardiovascular Magnetic Resonance of the European Society of Cardiology. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur Heart J 25 (2004) 1940-1965
60. Rickers C., Wilke N.M., Jerosch-Herold M., et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 112 (2005) 855-861
61. Moon J.C., Fisher N.G., McKenna W.J., and Pennell D.J. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart 90 (2004) 645-649
62. Suzuki J., Shimamoto R., Nishikawa J., et al. Morphological onset and early diagnosis in apical hypertrophic cardiomyopathy: a long term analysis with nuclear magnetic resonance imaging. J Am Coll Cardiol 33 (1999) 146-151
63. Schwammenthal E., Wichter T., Joachimsen K., Auffermann W., Peters P.E., and Breithardt G. Detection of regional left ventricular asynchrony in obstructive hypertrophic cardiomyopathy by magnetic resonance imaging. Am Heart J 127 (1994) 600-606
64. Dong S.J., MacGregor J.H., Crawley A.P., et al. Left ventricular wall thickness and regional systolic function in patients with hypertrophic cardiomyopathy. A three-dimensional tagged magnetic resonance imaging study. Circulation 90 (1994) 1200-1209
65. Kramer C.M., Reichek N., Ferrari V.A., Theobald T., Dawson J., and Axel L. Regional heterogeneity of function in hypertrophic cardiomyopathy. Circulation 90 (1994) 186-194
66. Sipola P., Lauerma K., Jaaskelainen P., et al. Cine MR imaging of myocardial contractile impairment in patients with hypertrophic cardiomyopathy attributable to Asp175Asn mutation in the alpha-tropomyosin gene. Radiology 236 (2005) 815-824
67. White R.D., Obuchowski N.A., Gunawardena S., et al. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: presurgical and postsurgical evaluation by computed tomography magnetic resonance imaging. Am J Card Imaging 10 (1996) 1-13
68. Arrive L., Assayag P., Russ G., Najmark D., Brochet E., and Nahum H. MRI and cine MRI of asymmetric septal hypertrophic cardiomyopathy. J Comput Assist Tomogr 18 (1994) 376-382
69. Paelinck B.P., de Roos A., Bax J.J., et al. Feasibility of tissue magnetic resonance imaging: a pilot study in comparison with tissue Doppler imaging and invasive measurement. J Am Coll Cardiol 45 (2005) 1109-1116
70. Choudhury L., Mahrholdt H., Wagner A., et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40 (2002) 2156-2164
71. Moon J.C., McKenna W.J., McCrohon J.A., Elliott P.M., Smith G.C., and Pennell D.J. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 41 (2003) 1561-1567
72. Moon J.C., Reed E., Sheppard M.N., et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43 (2004) 2260-2264
73. Moon J.C., Sachdev B., Elkington A.G., et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24 (2003) 2151-2155
74. Schulz-Menger J., Strohm O., Waigand J., Uhlich F., Dietz R., and Friedrich M.G. The value of magnetic resonance imaging of the left ventricular outflow tract in patients with hypertrophic obstructive cardiomyopathy after septal artery embolization. Circulation 101 (2000) 1764-1766
75. van Dockum W.G., ten Cate F.J., ten Berg J.M., et al. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol 43 (2004) 27-34
76. van Dockum W.G., Beek A.M., ten Cate F.J., et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 111 (2005) 2503-2508
77. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 97 (1998) 2536-2542
78. Crilley J.G., Boehm E.A., Blair E., et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 41 (2003) 1776-1782